ABSTRACT
Os inibidores da bomba de prótons (IBPs) são os fármacos mais utilizados no tratamento da doença do refluxo gastroesofágico (DRGE). Apesar de não reduzirem expressivamente o número de episódios de refluxo, propiciam mudança significativa na acidez. Isso quer dizer que continua havendo refluxo, porém os episódios são menos ácidos. Dessa forma consegue-se reduzir bastante os sintomas, sobretudo as queixas dependentes da acidez do material refluído.
Proton pump inhibitors (PPIs) are the most common medicine to treat gastroesophageal reflux disease (GERD). Although they don?t expressively reduce the amount of reflux episodes, it allows significantly changes in acidity. It means that reflux still exist, however, the episodes are less acid. As a result, symptoms can be reduced, mainly complaints due to acidity of the refluxed material.
Subject(s)
Humans , Gastroesophageal Reflux/surgery , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/drug therapy , Proton Pump Inhibitors/therapeutic use , GABA-B Receptor Agonists/therapeutic useABSTRACT
Gastroesophageal reflux disease (GERD) is one of the most common problems in gastrointestinal disorders. With the increase in our understanding on the pathophysiology of GERD along with the development of proton pump inhibitors, the diagnostic and therapeutic approaches to GERD have changed dramatically over the past decade. However, GERD still poses a problem to many clinicians since the spectrum of the disease has evolved to encompass more challenging presentations such as refractory GERD and extraesophageal manifestations. This has led to significant confusion regarding the optimal approach to these patients. This article aims to discuss current issues on GERD.